MS Center of Oklahoma

Oklahoma City, Oklahoma 73120

0 studies enrolling now · 4 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

Studies at this site

• Oral Cladribine in Early Multiple Sclerosis (MS) — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program — Completed